Researchers recommend ‘caution’ when using the chemotherapy busulfan in patients with Gilbert’s syndrome
Oct. 27, 2016
| By Susan Keown / Fred Hutch News Service
As many as one of every 10 people has Gilbert's syndrome, which is typically benign and has even been linked to long life. But new research suggests that busulfan, a bone marrow transplant drug, is extra risky in people with the condition.
Aided by six Hutchinson Center 'doctor partners,' local grade schoolers explore possible cancer cures, visit campus
May 29, 2012
| By Colleen Steelquist
Budding sixth-grade scientists from Snohomish's Dutch Hill Elementary School recently spent the day on the Fred Hutchinson Cancer Research Center campus, the culmination of a yearlong exploratory partnership with Center researchers.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.